バルナダス・モリンス博士は、腺療法における広範な研究と臨床経験を持つ、著名な乳がん専門医です。
アリ・ラファエル博士は、イスラエルの国家ゲノム医療イニシアチブであるPSIFASのTASMC腫瘍学プロジェクトを率いており、進行乳がん治療を専門としています。
乳がん治療の先駆者であるメリムスキー教授は、イスラエル最大の病院であるソラスキー医療センターの軟部組織・骨腫瘍ユニットを率いています。
主任医師および教授。四川大学華西病院（中国第2位）がんセンターの第1級専門家。中国人民解放軍総病院にてインターベンション放射線学の博士研究員課程を修了。複雑な腫瘍に対する多職種チーム（MDT）ケアを主導。肝臓がん、肺がん、膵臓がんに対する低侵襲インターベンション腫瘍学の専門家。
認定：WATA理事。CACAおよびCMDAのインターベンション、アブレーション、放射性シード、疼痛に関する委員会のメンバー。2023年、四川省医師会緩和ケア委員会の初代理事メンバーに就任。Chinese Journal of Interventional Imaging and Therapyの編集委員。Chinese Journal of Pain Medicineの編集委員。
2つの省科学技術プロジェクトおよび2つのNSFCプロジェクトを主導。40本以上の論文を発表し、30本以上で筆頭著者または責任著者を務める。最高インパクトファクター：10.73。肝細胞がん（HCC）コホート：TACE + レンバチニブ vs TACE + ソラフェニブ。OS（全生存期間）18.97ヶ月 vs 10.77ヶ月。PFS（無増悪生存期間）10.6ヶ月 vs 5.4ヶ月。ORR（客観的奏効率）66.8% vs 33.3%。
肖越勇教授は、中国人民解放軍総病院放射線診断科の主任医師です。低侵襲インターベンション腫瘍学の第一人者です。WATA（2025年〜）の初代会長を務めています。国際（2020年〜）およびアジア（2012年〜）凍結療法学会の会長です。また、腫瘍アブレーション規制に関するNHC専門家グループの副代表（2009年〜）も務めています。
CT/MRIガイド下での低侵襲手術を10万件以上実施してきました。化学アブレーション、RFA、MWA、凍結アブレーション、NanoKnife（IRE）を専門としています。中国にNanoKnifeアブレーションを導入し、発展させました。腫瘍凍結アブレーションとNanoKnifeに関する初の国家基準を主導しました。
受賞歴には、国家特別貢献賞（終身名誉）などがあります。中国医学教育協会から一等賞（2021年）を受賞しました。軍事医学功績賞で二等賞を2回（2016年、2018年）、中国抗癌協会から二等賞を2回（2019年、2022年）受賞しました。アジアのアブレーションマスターに選ばれました。研究実績には13件の中国特許が含まれます。4つのNSFCプロジェクトと1つのMOSTプロジェクトの主任研究員です。200本以上の論文を発表しており、そのうち110本以上が筆頭著者または責任著者であり、40本以上がSCIジャーナルに掲載されています。10件以上のアブレーションガイドラインやコンセンサス声明を主導してきました。
ソラック医師は乳がん治療を専門としており、トルコ有数の腫瘍学センターであるハジェテペ大学がん研究所でフェローシップ研修を修了しています。
ソウラスキー医療センター（イヒロフ）の婦人科腫瘍学および放射線治療の専門医。
セヴリーヌ・イボラ医師は、ゾーリンゲン市立病院の産婦人科部長を務め、ベルギッシュ乳腺センターにて乳がん治療を専門としています。
ステファンスキー医師はテルアビブ医療センターの腫瘍科入院部門を統括しており、乳がんの腺療法を専門としています。
ゾンネンブリック医師は、キイトルーダなどの最先端治療を含む、乳がんの包括的な腺療法を専門としています。彼の業績は国際的に認められ、数々の賞を受賞しています。
タフシン・オザトリ准教授は、イスティニエ・リヴ大学病院にて乳がん、肺がん、消化器がんを専門としています。
トラキア大学の医療腫瘍学教授で、がん治療において_doctor_10980_年以上の経験を持つ。
アレムダル医師は、メディカルパーク・アンタルヤ病院コンプレックスにて、乳がん治療に重点を置いた腫瘍内科を専門としています。
Zhang Jinshan, male, China’s First M.D. in the Radiation Medicine, CCI (Chinese College of Interventionalists) Master Interventionalist, Director of the Department of Former Radiological Diagnosis at Chinese PLA General Hospital(No.3 in China) Ph.D. of Medicine, Nagasaki University, Japan.
1980–1985: Completed doctoral studies at Nagasaki University, Japan
1968–present: Department of Radiology, Chinese PLA General Hospital
1988: Third Prize of the Military Science and Technology Progress Award
1989–present: Member of Radiological Society of North America(RSNA)
1990–2009: Standing Committee Member of the Radiology and Therapeutic Radiology Committee of the PLA
1991: Second Prize of the Military Science and Technology Progress Award
1992–2008: Group Leader of the Group of Intervention of Chinese Journal of Radiology
1992–2015: Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology
1993: Granted the Lifetime Special Government Allowance of the State Council
1993–2012: Deputy Chief Editor of Chinese Journal of Medical Image Technology
1994: Third Prize of the Military Science and Technology Progress Award
1997: Second Prize of the Military Science and Technology Progress Award
1997–2009: Standing Member of Chinese Society of Radiology
1999: Third Prize of the Military Science and Technology Progress Award
1999–2010: Deputy Director Member of Chinese Society of Interventional Oncology
2002: Second Prize of the Military Science and Technology Progress Award
2005: Third Prize of the Military Science and Technology Progress Award
Member of Radiological Society of North America(RSNA)
Standing Member of Chinese Society of Radiology
Group Leader of the Group of Intervention of Chinese Journal of Radiology
Deputy Director Member of Chinese Society of Interventional Oncology
Director Member of Beijing Medical Association Society of Interventional Radiology
Deputy Chief Editor of Chinese Journal of Medical Image Technology
Standing Member of Professional Committee of Radiological Medicine of the Chinese People’s Liberation Army
Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology
Awarded the Special Government Allowance of the State Council
Awarded three Second Prizes and four Third Prizes for Military Science and Technology Progress.
Awarded the honorary title of “Chinese College of Interventionalists(CCI) Master Interventionalist”
Led multiple national and provincial/ministerial scientific research projects, including two projects funded by the National Natural Science Foundation of China and two projects funded by the Department of Science and Technology of Sichuan Province.
In the pioneering development of interventional medicine in China, Zhang Jinshan has been an indispensable founder and leading figure. As China’s first overseas-trained doctoral graduate in radiological medicine, he returned to China in the 1980s after completing his studies abroad and introduced cutting-edge international interventional technologies to the country. Over more than four decades of dedicated practice and research, he has helped propel Chinese interventional medicine from its infancy to a position at the forefront of the global field through his exceptional clinical expertise and profound academic accomplishments.
Professor Zhang Jinshan has long been dedicated to the field of medical imaging and has developed distinctive expertise in selective and superselective interventional diagnosis and treatment for solid tumors such as liver cancer, demonstrating exceptional technical proficiency and profound academic accomplishment. Beginning in the 1990s, he led his team in pioneering the clinical application and research of TIPSS and B-ORTO in China, filling major gaps in the domestic field and opening new paths for the interventional management of gastrointestinal bleeding caused by portal hypertension secondary to liver cirrhosis. In addition, he has made groundbreaking contributions to the interventional diagnosis and treatment of peripheral vascular diseases, as well as to preoperative embolization for spinal tumors.
In the field of liver cancer treatment, Professor Zhang Jinshan not only led the development of standardized treatment protocols for liver cancer but also pioneered Transcatheter Arterial Chemoembolization with temporary Hepatic Vein Thrombosis (TACE-THVO) for primary liver cancer, bringing the efficacy of interventional therapy to a new level. In recognition of his outstanding clinical and scientific contributions, he was awarded the honorary title of “Chinese Master of Interventional Radiology” at the 2019 annual conference of the Chinese College of Interventionalists.
Professor Zhang Jinshan is not only a master clinician but also a driving force in the development of the discipline and a dedicated mentor in talent cultivation. He led his team in establishing one of China’s premier interventional therapy centers. As a doctoral supervisor, he has trained a large number of outstanding specialists and future leaders in interventional medicine, with many of his students and protégés now serving across the country. Academically, he has led multiple key national and military research projects, published more than 300 academic papers, and served as chief editor of three monographs, making remarkable contributions to the establishment of China’s academic framework for interventional medicine and the nationwide dissemination of its technologies.
From the laboratory to the operating room, and from academic podiums to grassroots hospitals, Professor Zhang Jinshan has consistently upheld the principles of “pioneering, innovation, pragmatism, and compassion". He has devoted his life to fulfilling the mission of a physician—relieving patients’ suffering through minimally invasive techniques and advancing the discipline through academic excellence—thereby establishing himself as a truly towering figure and one of the foremost authorities in the field of interventional medicine in China.
Professor Zhang Jinshan has achieved prolific academic accomplishments, having published over 300 academic papers covering areas such as interventional therapy for liver cancer, minimally invasive treatment of portal hypertension, interventional treatment of vascular diseases, and tumor ablation.
1. Zhang Jinshan, Wang Maoqiang. Experiments and Clinical Studies of transjugular intrahepatic portosystemic stent shunt (TIPSS). Chinese Journal of Radiology, 1993，27（6）：361-365.
Professor Zhang Jinshan is the first author. This is one of the early research papers in China that systematically elaborates on the TIPSS technique. Through animal experiments and clinical case analysis, it confirmed that TIPSS is a safe and effective minimally invasive method for treating portal hypertension and its complications, laying an important foundation for the promotion and application of this technique in China.
2.Zhang Jinshan, Li Huai. Clinical study on transcatheter arterial embolization with temporary hepatic vein occlusion for the treatment of primary liver cancer.Chinese Journal of Radiology, 1996，30（8）：521-524.
Professor Zhang Jinshan is the first author. He innovatively proposed the technique of "transcatheter arterial embolization with temporary hepatic vein occlusion." Clinical results demonstrated that this method can significantly increase the drug concentration within liver cancer lesions, reduce damage to normal liver tissue, and effectively improve the therapeutic outcomes for intermediate and advanced liver cancer, providing a novel strategy for the interventional treatment of liver cancer.
3. Zhang Jinshan, Wang Maoqiang, Li Huai. Interventional treatment of Budd-Chiari syndrome. Chinese Journal of Medical Imaging Technology, 1998，14（3）：189-191.
Professor Zhang Jinshan is the first author. This paper systematically summarizes the early experience in interventional treatment of Budd-Chiari syndrome in China, elaborating in detail on the key operational points and therapeutic efficacy of techniques such as percutaneous transluminal angioplasty and stent placement. It confirms that interventional therapy is the preferred minimally invasive method for Budd-Chiari syndrome, promoting the standardized development of treatment for this disease.
4.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical value of superselective hepatic arterial chemoembolization in the treatment of hypovascular liver cancer. Chinese Journal of Radiology, 2000，34（5）：335-337.
Professor Zhang Jinshan is the first author. Addressing the challenges in interventional treatment of hypovascular liver cancer, this paper explores the clinical efficacy of superselective hepatic arterial chemoembolization. The results indicate that this technique can precisely target the lesions and improve the treatment response rate, providing an important clinical basis for the interventional treatment of hypovascular liver cancer.
5. Zhang Jinshan, Li Huai, Wang Maoqiang. Interventional treatment of peripheral vascular stenosis and occlusion.Chinese Journal of Radiology, 2002，36（7）：612-614.
Professor Zhang Jinshan is the first author. This paper summarizes the interventional treatment experience of over 400 patients with peripheral vascular stenosis and occlusion, analyzing the indications and efficacy of techniques such as balloon angioplasty and stent placement. It confirms that interventional therapy is a safe and effective approach for peripheral vascular diseases, providing practical support for its clinical promotion.
6.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical application of CT-guided percutaneous puncture ablation in the treatment of abdominal tumors. Chinese Journal of Medical Imaging Technology, 2004，20（9）：1395-1397.
Professor Zhang Jinshan is the first author. This paper explores the application value of CT-guided percutaneous puncture techniques such as radiofrequency ablation and chemical ablation in the treatment of abdominal tumors. The clinical results show that this method is minimally invasive with reliable efficacy, offering a minimally invasive treatment option for patients with inoperable abdominal tumors.
7.Zhang Jinshan, Wang Maoqiang, Li Huai. Advances in the application of interventional therapy for benign prostatic hyperplasia. Chinese Journal of Radiology, 2006，40（8）：876-878.
Professor Zhang Jinshan is the corresponding author. This paper systematically reviews the cutting-edge advances in interventional therapy for benign prostatic hyperplasia, including the principles, procedures, and efficacy of techniques such as prostatic artery embolization and stent placement, providing new insights for the minimally invasive treatment of benign prostatic hyperplasia.
8.Zhang Jinshan, Li Huai, Wang Maoqiang. Discussion on the standardization of interventional therapy for liver cancer. Chinese Journal of Practical Surgery, 2008，28（10）：856-858.
Professor Zhang Jinshan is the corresponding author. Drawing on years of clinical experience and research findings, he led the discussion on standardized protocols for interventional therapy of liver cancer, covering key aspects such as preoperative assessment, treatment modality selection, and postoperative management, providing important references for the formulation of clinical guidelines for interventional therapy of liver cancer in China.
1. Interventional Radiology (People's Military Medical Press, 1995): The first monograph in China to systematically discuss the theories and techniques of interventional radiology. It comprehensively elaborates on the interventional diagnosis and treatment system for tumors, vascular diseases, and non-vascular diseases, becoming a classic essential textbook for interventional physicians in China.
2.Interventional Therapy for Liver Cancer (People's Health Press, 2001): Focusing on minimally invasive interventions for liver cancer, this book systematically summarizes techniques such as TACE, ablation, and vascular intervention, refines operational standards and the prevention and management of complications, and promotes the standardization of interventional therapy for liver cancer.
3.Interventional Treatment of Portal Hypertension (Science Press, 2005): This book systematically elaborates on minimally invasive techniques for portal hypertension, such as TIPSS and B-ORTO, covering experimental research, clinical procedures, long-term follow-up, and efficacy evaluation, filling the gap in monographs on interventional treatment of portal hypertension in China.
1.The National "Eighth Five-Year Plan" Scientific and Technological Key Project—Clinical and Basic Research on Comprehensive Interventional Therapy for Liver Cancer (Project Leader): This project systematically explored multimodal interventional strategies for liver cancer, established the core regimen of superselective TACE combined with local ablation, and significantly improved the therapeutic outcomes for intermediate and advanced liver cancer.
2.The Military "Ninth Five-Year Plan" Key Medical Scientific Research Project—Standardized Research on TIPSS for the Treatment of Portal Hypertension (Project Leader): This project formulated China's first operational standards and postoperative management guidelines for TIPSS, reduced the incidence of complications, and promoted the popularization of this technique throughout the military and across the country.
3.National Natural Science Foundation of China Project — Research on the Mechanism of Targeted Therapy for Liver Cancer Using Hepatic Vein Occlusion Combined with Chemoembolization (Project Leader): This project revealed the synergistic enhancement mechanisms of the innovative technique at the levels of hemodynamics, drug metabolism, and the tumor microenvironment, providing theoretical support for precision interventional therapy of liver cancer.
4.Military Clinical High-Tech Major Project-Establishment and Clinical Application of the Interventional Treatment Technology System for Complex Vascular Diseases (Project Leader): This project overcame interventional challenges in complex lesions such as Budd-Chiari syndrome, peripheral vascular occlusion, and vascular malformations, forming a complete technical system that has been promoted and applied widely.
ドイツの主要な多職種乳腺ユニットの臨床ディレクターであるシェルコ・キュンメルは、外科手術と最先端の研究を融合させています。
2001年よりハダッサ医療センターの腫瘍科部長を務めるウジエリ医師は、ホルモン療法や化学療法を含む乳がん治療を専門としています。
Conacem認定を受けた外科腫瘍医で、ガレニア病院にて乳腺がん治療を専門としています。
| 順位 | 医師 | 経験 | 適合する方 | 特色 | クリニックと所在地 | 診察 |
|---|---|---|---|---|---|---|
| #1 | 41年の経験 | 乳がんの腺療法 | GEICAMで指導的役割を担う主要研究者であり、臨床ケアと学術的卓越性を融合させています。ESMO、ASCO、SEOMから認定されています。 | スペイン | お問い合わせください | |
| #2 | 29年の経験 | ゲノムプロファイリングと進行乳がん | イスラエルの国家ゲノム医療イニシアチブを率いる精密腫瘍学のパイオニア。ペムブロリズマブおよび術前補助免疫療法を研究する臨床試験の治験責任医師。 | イスラエル | から $750 | |
| #3 | 41年の経験 | 腺温存乳がん治療 | イスラエル屈指の軟部組織腫瘍ユニットを率い、専門的な腺温存プロトコルを導入。ESMOファカルティメンバーであり、元国家腫瘍学会会長。 | イスラエル | から $950 | |
| #4 | 20年の経験 | 乳がん治療 | ハジェテペがん研究所でのフェローシップ研修およびMDアンダーソンでの追加研修を修了。複雑な乳がん症例を専門とする。 | トルコ | から $100 | |
| #5 | 39年の経験 | 乳がんの腺療法 | 婦人科腫瘍学と放射線治療を専門とし、標的を絞った腺療法を提供。最高レベルの医療機関であるソウラスキー医療センターに所属。 | イスラエル | お問い合わせください | |
| #6 | 19年の経験 | 乳がん治療 | 乳がんの診断と治療の認定を受けた婦人科腫瘍学の専門家。専門の乳腺センターを率い、高度なロボット支援技術を駆使しています。 | ドイツ | お問い合わせください | |
| #7 | 26年の経験 | 乳がんの腺療法 | 主要な医療センターで腫瘍科入院部門を率いています。革新的な乳がん治療のための先駆的な臨床研究に積極的に携わっています。 | イスラエル | から $750 | |
| #8 | 19年の経験 | キイトルーダによる標的療法 | キイトルーダ（ペムブロリズマブ）をはじめとする高度な治療を専門としています。ESMOおよびISCORTから表彰されています。世界トップクラスの研究所で研修を受けています。 | イスラエル | お問い合わせください | |
| #9 | 2016年の経験 | 乳がん治療 | 腫瘍学における豊富な経験を持つ乳がんの専門家。トルコの主要病院で10年の診療実績を持つ准教授。 | トルコ | お問い合わせください | |
| #10 | 29年の経験 | 乳がんの腺療法 | 腺療法を含む乳がん治療を専門とする経験豊富な教授。トラキア大学でフェローシップを修了し、腫瘍学において指導的役割を担っている。 | トルコ | お問い合わせください |